Clinical trial NCT00567931 (phase 1, status: completed)
Conditions: unspecified adult solid tumor, protocol specific
ICD codes: H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: 1-methyl-d-tryptophan
SMILES: CN1C=C(C[C@@H](N)C(O)=O)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed solid malignancy that is metastatic or unresectable and for
             which standard effective antineoplastic therapy does not exist or is no longer
             effective

          -  Patients are eligible for enrollment into the trial regardless of the types of
             previous therapies administered

          -  Patients with known brain metastases will only be eligible after their tumors have
             been treated with definitive resection and/or radiotherapy and they are neurologically
             stable for at least 1 month off steroids

               -  No known untreated brain metastases

          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

          -  Life expectancy > 4 months

          -  WBC ≥ 3,000/μL

          -  ANC ≥ 1,500/μL

          -  Platelet count ≥ 100,000/μL

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 times ULN

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  No history of gastrointestinal disease causing malabsorption or obstruction,
             including, but not limited to, any of the following:

               -  Crohn's disease

               -  Celiac sprue

               -  Tropical sprue

               -  Bacterial overgrowth/blind-loop syndrome

               -  Strictures

               -  Adhesions

               -  Achalasia

               -  Bowel obstruction

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double-method contraception during and for at
             least 1 month after completion of study treatment

          -  No history of allergic reactions (significant urticaria, angioedema, anaphylaxis)
             attributed to compounds of similar chemical or biologic composition to
             1-methyl-d-tryptophan (including L-tryptophan or 5-hydroxy-tryptophan supplements)

          -  No active autoimmune disease (i.e., psoriasis, extensive atopic dermatitis, asthma,
             inflammatory bowel disorder, multiple sclerosis, uveitis, vasculitis), chronic
             inflammatory condition, or any condition requiring concurrent use of any systemic
             immunosuppressants or steroids for any reason

          -  Mild-intermittent asthma requiring only occasional beta-agonist inhaler use or mild
             localized eczema allowed

          -  No uncontrolled concurrent illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Myocardial infarction or percutaneous coronary interventions within the past 6
                  months

               -  Cardiac arrhythmia

               -  Active autoimmune diseases

               -  Major psychiatric illness or social situation that would limit compliance with
                  study requirements as judged by the primary investigator at each site

          -  Patients with well-controlled, chronic medical conditions under the supervision of the
             patient's primary physician (i.e., hypertension, hyperlipidemia, coronary heart
             disease, diabetes mellitus) are eligible

          -  No HIV-positive patients or patients with other acquired/inherited immunodeficiencies

          -  No other active malignancy

          -  No concurrent immunosuppressants, including steroids

          -  Recovered from all prior therapy

          -  No prior gastric bypass surgery

          -  No prior extensive small bowel resection

          -  No prior experimental active immunotherapy consisting of targeted monoclonal
             antibodies or pharmaceutical compounds

               -  Commercially available active immunotherapy (e.g., adjuvant interferon) must have
                  completed therapy over 1 year prior to enrollment and have no evidence of
                  autoimmune sequelae

          -  Prior therapy with approved monoclonal antibodies (e.g., bevacizumab, cetuximab,
             panitumumab, or trastuzumab) allowed

          -  At least 4 weeks since prior and no other concurrent investigational agents

          -  More than 4 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas
             or mitomycin C)

          -  No concurrent supplements containing L-tryptophan or derivatives

          -  No patients with an allo-transplant of any kind (including those with a xenograft
             heart valve)

          -  No other concurrent commercial agents or therapies